A PHASE 2, UMBRELLA STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OF INVESTIGATIONAL AGENTS FOR NEWLY DIAGNOSED, HIGH-RISK, EARLYSTAGE TRIPLE-NEGATIVE BREAST CANCER

Registry ID

MK-5890-003

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

MERCK CANADA INC

Last update

2025-03-19

Conditions

• BREAST CANCER TRIPLE NEGATIVE

Related clinical trials

• A PHASE II STUDY OF FIRST-LINE SACITUZUMAB GOVITECAN IN ADVANCED UNTREATED TRIPLE NEGATIVE BREAST CANCER PATIENT
• OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY
• A PHASE III, OPEN-LABEL, RANDOMISED STUDY OF NEOADJUVANT DATOPOTAMAB DERUXTECAN (DATO-DXD) PLUS DURVALUMAB FOLLOWED BY ADJUVANT DURVALUMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS NEOADJUVANT PEMBROLIZUMAB PLUS CHEMOTHERAPY FOLLOWED BY ADJUVANT PEMBROLIZUMAB WITH OR WITHOUT CHEMOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED TRIPLE-NEGATIVE OR HORMONE RECEPTOR-LOW/HER2-NEGATIVE BREAST CANCER
• A PHASE 3 OPEN-LABEL, RANDOMISED STUDY OF DATOPOTAMAB DERUXTECAN¿(DATODXD) WITH OR WITHOUT DURVALUMAB VERSUS INVESTIGATOR¿S CHOICE OF THERAPY IN PATIENTS WITH STAGE I-III TRIPLE-NEGATIVE BREAST CANCER WHO HAVE RESIDUAL INVASIVE DISEASE IN THE BREAST AND/OR AXILLARY LYMPH NODES AT SURGICAL RESECTION FOLLOWING NEOADJUVANT SYSTEMIC THERAPY
• A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SACITUZUMAB GOVITECAN VERSUS TREATMENT OF PHYSICIAN¿S CHOICE IN PATIENTS WITH PREVIOUSLY UNTREATED, LOCALLY ADVANCED, INOPERABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER WHOSE TUMORS DO NOT EXPRESS PD-L1 OR IN PATIENTS PREVIOUSLY TREATED WITH ANTI-PD-(L)1 AGENTS IN THE EARLY SETTING WHOSE TUMORS DO EXPRESS PD-L1
• A PHASE II STUDY OF CFI-400945 AND DURVALUMAB IN PATIENTS WITH ADVANCED/METASTATIC TRIPLE NEGATIVE BREAST CANCER (TNBC)

View on source registry